GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » International Stem Cell Corp (OTCPK:ISCO) » Definitions » Change In Other Working Capital

International Stem Cell (International Stem Cell) Change In Other Working Capital : $-0.24 Mil (TTM As of Mar. 2024)


View and export this data going back to 2006. Start your Free Trial

What is International Stem Cell Change In Other Working Capital?

International Stem Cell's Change In Other Working Capital for the quarter that ended in Mar. 2024 was $-0.07 Mil. It means International Stem Cell's Other Working Capital declined by $0.07 Mil from Dec. 2023 to Mar. 2024 .

International Stem Cell's Change In Other Working Capital for the fiscal year that ended in Dec. 2023 was $-0.23 Mil. It means International Stem Cell's Other Working Capital declined by $0.23 Mil from Dec. 2022 to Dec. 2023 .

International Stem Cell Change In Other Working Capital Historical Data

The historical data trend for International Stem Cell's Change In Other Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

International Stem Cell Change In Other Working Capital Chart

International Stem Cell Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Other Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.30 -0.32 -0.34 -0.18 -0.23

International Stem Cell Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Change In Other Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.05 -0.06 -0.06 -0.06 -0.07

International Stem Cell Change In Other Working Capital Calculation

Change In Other Working Capital is any increase or decrease between periods of other working capital that are not otherwise classified.

Change In Other Working Capital for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.24 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

International Stem Cell Change In Other Working Capital Related Terms

Thank you for viewing the detailed overview of International Stem Cell's Change In Other Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

International Stem Cell (International Stem Cell) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » International Stem Cell Corp (OTCPK:ISCO) » Definitions » Change In Other Working Capital
Comparable Companies
MYMXD BLPH XSNX RSPI KTRA SQZB CNBX RGTPQ LADX RVLPQ OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XKRX:068270 BNTX ALNY
Traded in Other Exchanges
N/A
Address
9745 Businesspark Avenue, San Diego, CA, USA, 92131
Website
https://www.internationalstemcell.com
International Stem Cell Corp is a clinical-stage biotechnology company. It is focused on therapeutic and biomedical product development with multiple long-term therapeutic opportunities. The company develops different cell types from its stem cells that may result in therapeutic products. The clinical applications of the company include neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; Liver cells, which are used to treat a variety of congenital and acquired liver diseases; and retinal cells and three-dimensional eye structures. It operates in three segments, the therapeutic market, the biomedical market, and the anti-aging market. The Biomedical products business segment accounts for the majority of revenue.
Executives
Paul V Maier director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Andrei Semechkin 10 percent owner 1 OVERLOOK DR. UNIT 11, AMHERST NH 03031
Sofya Bakalova officer: Dir. of Legal Affairs & Oper. 5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Wright Don director 2829 RUCKER AVE, 3RD FLOOR, EVERETT WA 98201
Jennifer Stephens officer: Acting Chief Financial Officer 5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Mahnaz Ebrahimi officer: Chief Financial Officer 5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Rouslan Semechkin director, 10 percent owner 2595 JASON CT, OCEANSIDE CA 92056
Tibor Jay Novak officer: Interim CFO 5950 PRIESTLY DRIVE, CARLSBAD CA 92008
John Simon Craw officer: Executive Vice President 5950 PRIESTLY DRIVE, CARLSBAD CA 92008
James H Berglund director C/O INTERNATIONAL STEM CELL CORPORATION, 5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Ar Partners Llc 10 percent owner 5950 PRIESTLY DR., CARLSBAD CA 92008
Kurt Andrew May officer: President and COO 5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Linh T Nguyen officer: Chief Financial Officer 5950 PRIESTLY DR., CARLSBAD CA 92008
Jeffrey Janus director, officer: President 2595 JASON COURT, OCEANSIDE CA 92056
Charles J Casamento director 99 BELBROOK WAY, ATHERTON CA 94027